

Evaluation Form

This interactive and evidence-based program was developed by leading Canadian experts to address the importance of strict management of low density lipoprotein cholesterol (LDL-C) for patients with atherosclerotic cardiovascular disease as well as provide a timely review of the results of recently completed clinical trials and their applicability to routine clinical practice

DATE	2019/08/21	LOCATION		location
Demographics				
Physician: 🖵 Yes	□ No □ Other Please	enerify		
Type of Practice:		Salo	☐ Hospital ☐ Othe	Γ
LEARNING OBJECTIVE	S: New Harizons in Dyslipider	nia Management in Primary Car	e	
After participating in	this activity, I am now better	able to:		
. D: .!	IDI DI COLO			
	-	r risk reduction with emphasis on t		
Strongly disagree	Disagree	Neutral	Agree	Strongly agree
Evaluate recomment vascular disease	ndations for lipid lowering agents	s beyond or in addition to statin then	rapy for patients with a	u u
Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5
Explain the mechan to patient manager		ertase subtilisin/kexin type 9 (PCSI	(9) inhibitors and apply	the latest clinical data
Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5
4. Apply best guidelin	e practice recommendations into	o routine clinical practice based on	specific patient charac	teristics
Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5
LEARNING OBJECTIVES	: Case 1 - Diabetes & Cardio	vascular Disease		
Upon completion of t	his case based session, partic	pants will be able to:		
1. Assess your patien	ts with diabetes for risk of macr	o and microvascular disease		
Strongly disagree	Disagree	Neutral	Agree	Strongly agree
L	2	3	4	5
2. Use the ABCDES of	vascular protection for your pat	ients with diabetes		
Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5
Use appropriate ac	lditional therapies to help reach	the LDL-C target		
Strongly disagree	Disagree	Neutral	Agree	Strongly agree
1	2	3	4	5

Strongly disagree	Disagree	Neutral		Agree	Strongly agree
1	2	3		4	5
id you perceive any deg	ree of bias in any pa	art of the program?	Yes 🗅	No	
so, please explain:					
his Program			se indicate with Ca ng this educationa	AnMEDS roles you fo	elt were addressi
ontent enhanced my know	/ledge		_	•	
trongly disagree Ne	eutral Stron	ngly agree	Family Medicine Exp	ert	
ddressed my most pressi	3 4	5	I Collaborator		
		igly agree	I Communicator		
1 2	3 4	5	l Manager		
romoted improvements o		_	I Health Advocate		
rongly disagree Nei	utral Strong	gly agree 5	l Professional		
as scientifically rigorous			I Scholar		
rongly disagree Ne		igly agree	Cilolai		
e., case studies, discussion, Q l	GA, etc)	_			
e., case studies, discussion, Q & trongly disagree Ne 1 2 rovided an opportunity fo	effective opportunities 6A, etc) outral Stron 3 4 r interaction with my	ngly agree 5 peers			
rovided an opportunity for trongly disagree Ner	effective opportunities 6A, etc) utral Stron 3 4 r interaction with my utral Stron 3 4	igly agree 5 peers igly agree 5			
e., case studies, discussion, Q & trongly disagree Ne rovided an apportunity for trongly disagree Ne 2 ased on your participat I gained new strategi I plan to implement no I need more informatical This program will not	effective opportunities 6A, etc) outral Stron 3 4 r interaction with my outral Stron 3 4 ion in this program, ies/skills/information the ew strategies/skills/information before I can implement the change my practice, as	igly agree 5 peers igly agree	ctice. mation into my pract ent with the informat		
e., case studies, discussion, Q & trongly disagree Ne N	effective opportunities 6A, etc) outral Stron 3 4 r interaction with my outral Stron 3 4 ion in this program, ies/skills/information the w strategies/skills/information the w strategies/skills/information before I can implement the change my practice, as the cha	peers please select all applicable hat I can apply to my area of pra ormation into my practice. nent new strategies/skills/infor s my current practice is consist s I do not agree with the informa	ctice. mation into my pract ent with the informat tion presented.		

This program has received an educational grant and in-kind support from Amgen Canada